RBP-7000 (risperidone depot)
Schizophrenia
ApprovedMarketed (as PERSERIS®)
Key Facts
About Indivior PLC
Indivior PLC is a leader in addiction medicine, dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. The company's mission centers on delivering life-changing medicines and digital therapeutics to patients with substance use disorders and co-occurring mental illnesses. Its commercial success is anchored by SUBOXONE® film, and it is strategically expanding its portfolio with novel long-acting injectables like SUBLOCADE® and PERSERIS®, and exploring next-generation treatments. Indivior operates as a public company, navigating a complex regulatory and competitive landscape while addressing one of society's most pressing public health challenges.
View full company profileOther Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| DSP-2230 (ulotaront) | Sumitomo Pharma | Phase 3 |
| COBENFY® (xanomeline/trospium) | Zai Lab | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |
| Fanapt® (iloperidone) | Vanda Pharmaceuticals | Approved |
| Fanapt® (iloperidone) one month injectable | Vanda Pharmaceuticals | In Development |